Skip to main content
SpringerLink
Log in

Alteplase is useful in some indications other than myocardial infarction

  • New Drugs and Therapeutic
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marder VJ. Thrombolytic therapy: overview of results in major vascular occlusions. Thromb Haemost 1995 Jul; 74(1): 101–5

    PubMed  CAS  Google Scholar 

  2. Gillis JC, Wagstaff AJ, Goa KL. Alteplase: a reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction. Drugs 1995 Jul; 50(1): 102–36

    Article  PubMed  CAS  Google Scholar 

  3. Wagstaff AJ, Gillis JC, Goa KL. Alteplase: a reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction. Drugs 1995 Aug; 50(2): 289–316

    Article  PubMed  CAS  Google Scholar 

  4. Francis CW, Marder VJ. Fibrinolytic therapy for venous thrombosis. Prog Cardiovasc Dis 1991 Nov/Dec; 34(3): 193–204

    Article  PubMed  CAS  Google Scholar 

  5. Genentech Inc. Alteplase recombinant prescribing information. South San Francisco, California, USA, 1995

  6. Goldhaber SZ, Haire WED, Feldstein ML, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993 Feb 27; 31: 507–11

    Article  Google Scholar 

  7. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988 Aug 6; 2: 293–8

    Article  PubMed  CAS  Google Scholar 

  8. Goldhaber SZ, Kessler CM, Heit J, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992 Jul; 20: 24–30

    Article  PubMed  CAS  Google Scholar 

  9. Goldhaber SZ, Agnelli G, Levine MN, et al. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. Chest 1994; 106: 718–24

    Article  PubMed  CAS  Google Scholar 

  10. Sors H, Pacouret G, Azarian R, et al. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. Chest 1994; 106: 712–7

    Article  PubMed  CAS  Google Scholar 

  11. Verhaege R, Besse P, Bounameaux H, et al. Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis. Thromb Res 1989 Jul 1; 55: 5–11

    Article  Google Scholar 

  12. Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990 Mar; 88: 235–40

    Article  PubMed  CAS  Google Scholar 

  13. Turpie AGG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest 1990 Apr; 97 Suppl.: 172–5

    Google Scholar 

  14. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischaemia of the lower extremity. Ann Surg 1994; 220(3): 251–68

    Article  Google Scholar 

  15. The TIMI IIIA Investigators. Early effects of tissue type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischaemic cardiac pain at rest; results of the Thrombolysis in Myocardial Ischaemia (TIMI IIIA) trial. Circulation 1993; 87: 38–52

    Article  Google Scholar 

  16. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction; results of the Thrombolysis in Myocardial Ischaemia (TIMI IIIB) trial. Circulation 1994; 89: 1545–56

    Article  Google Scholar 

  17. Verstraete M, Bachmann F, Davidson JF, et al. The present status of thrombolytic treatment in noncardiac disorders. J Intern Med 1994; 236: 447–54

    Article  PubMed  CAS  Google Scholar 

  18. Barnes J. ECASS researchers cannot recommend alteplase for stroke. Inpharma 1995 Feb; 18(974): 3–4

    Google Scholar 

  19. Adams HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischaemic stroke. Stroke 1994 Sep; 25(9): 1901–14

    Article  PubMed  Google Scholar 

  20. British National Formulary No. 29. London: The Pharmaceutical Press, 1995; 105–6

  21. Buar FW, Verheugt FW, Col J, et al. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation 1992 Jul; 86: 131–7

    Article  Google Scholar 

  22. Anon. Some stroke patients may benefit from streptokinase. Inpharma 1995 Mar 11; (977): 5

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alteplase is useful in some indications other than myocardial infarction. Drugs Ther. Perspect 6, 1–4 (1995). https://doi.org/10.2165/00042310-199506110-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506110-00001

Search

Navigation